An AI-designed inhibitor selectively targets the 3-hydroxy-3-methylglutaryl-CoA reductase enzyme to combat drug resistance in prostate cancer therapies. This advancement utilizes machine learning techniques for enzyme design and holds implications for treatment protocols in global healthcare systems, particularly affecting male demographics parallel to the rise in prostate cancer cases.
Read More:
- š phys.org